The Evolving Treatment Landscape for Adults with MASH: Results from a Phase 3 Trial

Join us for a focused look at clinical data from a phase 3 trial, detailing the 72-week efficacy and safety of a treatment for adults with noncirrhotic MASH and moderate to advanced fibrosis. The session will outline how these results may support care for appropriate patients with this chronic liver disease.

Industry Supporter: Novo Nordisk, Inc.